BC Extra | Jun 14, 2019
Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells   The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in...
BC Week In Review | Jun 14, 2010
Company News

ImaginAb, Agency for Science, Technology and Research deal

ImaginAb and A*STAR partnered to reengineer an antibody against protein tyrosine phosphatase type IVA 3 ( PTP4A3 ; PRL3 ) into an imaging agent to study the biology of the target in humans. Further terms were not...
Items per page:
1 - 2 of 2